Tolvaptan
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
Tolvaptan: Renal-hepatic-pancreatic dysplasia
One-Sentence Summary
Tolvaptan is a vasopressin V2 receptor antagonist, originally used for inappropriate ADH syndrome (SIADH), nephrogenic syndrome of inappropriate antidiuresis and polycystic kidney disease. with no registered clinical trials for this specific subtype but 20 publications, including 2 randomised controlled trials, supporting the broader ADPKD direction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Renal-hepatic-pancreatic dysplasia |
| TxGNN Prediction Score | 0.9998 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Tolvaptan is a selective vasopressin V2 receptor antagonist. In polycystic kidney disease, V2 receptor activation raises cAMP in renal tubular cells, which drives cyst growth and fluid secretion. Blocking the V2 receptor lowers cAMP and may slow cyst expansion.
The predicted indication belongs to the same ADPKD/PKD family as one of the drug’s existing indications. It is therefore largely an on-label or closely related use rather than a true repurposing. The PKD3 subtype (GANAB-associated) has not been specifically tested. The evidence is inferred from the broader ADPKD data, in particular the two pivotal randomised trials (TEMPO 3:4 and REPRISE) published in the New England Journal of Medicine.
Clinical Trial Evidence
Currently no related clinical trials registered for this specific predicted indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23121377 | 2012 | RCT | N Engl J Med | Tolvaptan in ADPKD (TEMPO 3:4). Vasopressin V2 antagonists inhibited cyst growth and slowed the decline of kidney function in preclinical studies. |
| 29105594 | 2017 | RCT | N Engl J Med | Tolvaptan in later-stage ADPKD. Builds on the earlier trial, which showed slower kidney volume growth and eGFR decline but more liver enzyme elevations. |
| 39356039 | 2024 | Systematic Review | Cochrane Database Syst Rev | Interventions for preventing ADPKD progression, including disease-modifying agents. |
| 40126492 | 2025 | Review | JAMA | Comprehensive review of ADPKD, the most common inherited kidney disorder. |
| 41771281 | 2026 | Review | Lancet | The strong evidence base for tolvaptan as a disease-modifying treatment supports its early use in patients at high risk of kidney failure. |
| 35487607 | 2022 | Review | Clin Liver Dis | Polycystic kidney/liver disease. Tolvaptan can slow the deterioration of renal function and cyst growth in ADPKD. |
| 40844441 | 2025 | Review | Am J Kidney Dis | Core curriculum. Disease-modifying therapy is recommended for patients at risk of progression to kidney failure. |
| 40726372 | 2025 | Review | Curr Opin Nephrol Hypertens | Tolvaptan remains the only FDA-approved therapy targeting disease progression; new therapies are in the pipeline. |
| 40268755 | 2025 | Review | Ren Fail | Overview of recent genetic and clinical advances in ADPKD. |
| 35227907 | 2022 | Preclinical | Vasc Pharmacol | Tolvaptan reduced experimental abdominal aortic aneurysm in mice, a different disease context. |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 233664 | Vaptan 15mg Tablet (Steadfast Medishield) | Strip of 7 tablets | Not specified |
| Registration No. 221905 | Tolsama 30mg Tablet (MSN Laboratories) | Strip of 4 tablets | Not specified |
| Registration No. 201963 | Shiokem 15mg Tablet (Alkem Laboratories) | Strip of 4 tablets | Not specified |
| Registration No. 150758 | Natrise 30 Tablet (Sun Pharmaceutical) | Strip of 4 tablets | Not specified |
| Registration No. 185349 | Resodim 30 Tablet (Lupin) | Strip of 4 tablets | Not specified |
A total of 20 valid single-ingredient registrations exist, all oral tablets.
Safety Considerations
- Hepatotoxicity: The ADPKD trials reported more elevations in aminotransferase and bilirubin levels. Liver enzyme monitoring is advised.
- Drug Interactions (100 interactions recorded; main ones listed):
- Major: Clarithromycin
- Moderate: Aprepitant, Dexamethasone, Rolapitant, Miconazole, Empagliflozin, Eliglustat, Loperamide, Naltrexone, Rifaximin, and several potassium products (potassium chloride, citrate, bicarbonate, gluconate)
- Minor: Fidaxomicin, Naloxegol, Prucalopride
- Manage aquaresis-related adverse effects (excess urine output and thirst), and review the high CYP3A4 interaction burden.
For full warnings, please refer to the package insert.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Two large randomised trials and several reviews support tolvaptan in ADPKD, and the predicted indication is in the same disease family as an existing indication. The PKD3 subtype has not been tested directly, and liver safety and interactions require active management.
To proceed, the following is needed:
- Package insert warnings and contraindications for the India products (currently unavailable and blocking the safety screen)
- Detailed mechanism of action data
- Subtype-specific evidence for PKD3 (GANAB-associated) disease
- A liver enzyme monitoring plan and an interaction management plan (CYP3A4 inhibitors and inducers)
Other predictions (not recommended at present): The other nine predicted indications have little or no support. Joubert syndrome with renal defect is a research question only, based on indirect mechanistic reasoning with no tolvaptan data. The remainder, including renal-hepatic-pancreatic dysplasia, karyomegalic interstitial nephritis, thoracic malformation and hypertrichosis, have no clinical evidence and are on Hold.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.